We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CYP3A4*22 may increase bleeding risk in ticagrelor users.
- Authors
Liedes, Hilkka; Pajula, Juha; Vuorinen, Anna‐Leena; De Pretis, Francesco; van Gils, Mark; Harno, Kari; Lehto, Mika; Niemi, Mikko; Lähteenmäki, Jaakko
- Abstract
Keywords: adverse drug events; antiplatelet drugs; ischemic heart disease; pharmacogenetics; polymorphism; precision medicine EN adverse drug events antiplatelet drugs ischemic heart disease pharmacogenetics polymorphism precision medicine 202 207 6 07/07/23 20230801 NES 230801 INTRODUCTION AND BACKGROUND The conventional treatment for acute coronary syndromes (ACS) includes percutaneous coronary intervention with stent placement requiring dual antiplatelet therapy with acetylsalicylic acid (ASA) and an antiplatelet drug (clopidogrel, prasugrel or ticagrelor). Adverse drug events, antiplatelet drugs, ischemic heart disease, pharmacogenetics, polymorphism, precision medicine Use of ASA was extracted from patient records because ASA, as an over-the-counter drug, is not recorded in the drug purchase registry. Neither I CYP3A5*3 i nor I CYP4F2 i rs3093135 carrier status was associated with the occurrence of bleeding events.
- Subjects
TICAGRELOR; PHARMACOGENOMICS; THROMBIN receptors; HEMORRHAGE; ST elevation myocardial infarction; BLOOD coagulation factors; ACUTE coronary syndrome; BLOOD platelet aggregation
- Publication
Basic & Clinical Pharmacology & Toxicology, 2023, Vol 133, Issue 2, p202
- ISSN
1742-7835
- Publication type
Article
- DOI
10.1111/bcpt.13884